Jan. 13, 2026 -- Minovia Therapeutics Ltd. (“Minovia” or the “Company”), a clinical-stage biotechnology company developing novel therapies to treat mitochondrial diseases and combat age-related decline, today announced that it has been granted two new U.S. patents that further expand and strengthen its global intellectual property portfolio supporting its proprietary Mitochondrial Augmentation Therapy (MAT) platform. The newly granted patents cover mitochondrial augmentation therapy for primar

Commercial launch in Switzerland anticipated in H2 2026 January 15, 2026 – Santhera Pharmaceuticals (SIX: SANN) announces that the Swiss Agency for Therapeutic Products (Swissmedic), has approved AGAMREE® (vamorolone) for the treatment of Duchenne muscular dystrophy (DMD) in patients four years of age and older. Dario Eklund, Chief Executive Officer of Santhera, commented: “As a proudly Switzerland-based business, securing Swissmedic approval represents an important achievement, and marks our

Jan. 13, 2026 -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”), a clinical-stage biotechnology company advancing regenerative medicine solutions, today announced positive interim 180-day follow-up data from its FDA-cleared ADAPT clinical trial evaluating CELZ-201 (Olastrocel), the Company’s proprietary perinatal tissue-derived cell therapy for chronic lower back pain associated with degenerative disc disease. The study produced statistically si

The CGuard® Prime Carotid Stent System demonstrated the lowest 30-day and 1-year primary endpoint major adverse event rates of any pivotal study of carotid stenting (CAS) Jan. 12, 2026 -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that results from the Company’s C-GUARDIANS pivotal trial have now been published in the Journal of the American College of Cardiology (JACC). The da

– Ribupatide (KAI-9531) aims to address critical need for greater weight loss, especially for people living with a BMI of 35 kg/m2 or greater – – KaiNETIC program includes three Phase 3 clinical trials in adults living with obesity or overweight – Jan. 12, 2026 -- Kailera Therapeutics, Inc., an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the randomization of the first participants in the KaiNETIC global Phase 3 clinical progr

First BGE-102 MAD cohort completed in obese individuals with elevated hsCRP receiving 120 mg QD; demonstrated rapid and profound reduction in inflammatory markers BGE-102 achieved 86% reduction in hsCRP at Day 14, with 93% of participants reaching normalized levels ( BGE-102 demonstrated significant reductions in IL-6, a key driver of systemic inflammation and cardiovascular risk, and fibrinogen, an independent predictor of cardiovascular events BGE-102 was well tolerated with a favorable safety

• Patient 1 of Cohort 1 has now completed the 24-month follow-up timepoint, and at month-24 post-treatment Patient 1 continued to demonstrate the powerful disease-modifying effects of BB-301, with deepening improvements in post-swallow residue and total dysphagic symptom burden as compared to the 12-month follow-up timepoint • Patient 4 of Cohort 1 continued to experience strong response to BB-301 at the 12-month follow-up timepoint • The first 4 patients enrolled into Cohort 1 have completed th

As part of the branding process, Polyrizon conducted comprehensive trademark screening across the U.S. and European markets Jan. 08, 2026 -- Polyrizon Ltd. Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal protective solutions, today announced that it has completed the branding process for its PL-14 allergy blocker, which will be marketed under the brand name NASARIX™. NASARIX™ is based on Polyrizon’s proprietary Cap

Database locks for studies on actinic keratosis (AK) and acne vulgaris achieved on January 5, 2026 Data generated will support key regulatory milestones for Ameluz PDT in both indications AK and acne are the two most commonly diagnosed skin disorders in the US1 Jan. 08, 2026 -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today announced the successful database

Jan. 08, 2026 -- Marius Pharmaceuticals, Inc. today announced the company will initiate a new post-marketing clinical study for potential label expansion evaluating KYZATREX® (testosterone undecanoate) CIII capsules in men ages 65–80 with hypogonadism. KYZATREX is a prescription drug used to treat adult men who have low or no testosterone levels due to certain medical conditions. As men age, the effects of low testosterone can intersect with broader age-related changes, influencing energy, mob